Search research articles
Contact Us
Filters
Showing results (1611-1620 of 1,873) with videos related to
Page
of 188
Sort By:
Circulation
|
November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
Diabetes Care
|
December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
Heart Failure Reviews
|
February 5, 2015
Site selection for heart failure clinical trials in the USA
Matthew E Harinstein, Javed Butler, Stephen J Greene, et al.
European Heart Journal
|
May 23, 2023
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Safia Chatur, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure
|
May 22, 2023
Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial
Safia Chatur, Jonathan W Cunningham, Muthiah Vaduganathan, et al.
JACC. Heart Failure
|
December 6, 2025
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial
Finnian R Mc Causland, Safia Chatur, Muthiah Vaduganathan, et al.
European Journal of Heart Failure
|
May 16, 2025
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
Misato Chimura, Mingming Yang, Alasdair D Henderson, et al.
JACC. Heart Failure
|
March 15, 2025
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
Kieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
JAMA Cardiology
|
April 17, 2024
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial
Ravi B Patel, Frank E Silvestry, Jan Komtebedde, et al.
Diabetes, Obesity & Metabolism
|
April 8, 2024
Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial
Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Daniel Modin, et al.
Page
of 188
Search research articles
Search
Showing results (1611-1620 of 1,873) with videos related to
Sort By:
Page
of 188
Circulation
|
November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
Diabetes Care
|
December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
Heart Failure Reviews
|
February 5, 2015
Site selection for heart failure clinical trials in the USA
Matthew E Harinstein, Javed Butler, Stephen J Greene, et al.
European Heart Journal
|
May 23, 2023
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Safia Chatur, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure
|
May 22, 2023
Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial
Safia Chatur, Jonathan W Cunningham, Muthiah Vaduganathan, et al.
JACC. Heart Failure
|
December 6, 2025
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial
Finnian R Mc Causland, Safia Chatur, Muthiah Vaduganathan, et al.
European Journal of Heart Failure
|
May 16, 2025
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
Misato Chimura, Mingming Yang, Alasdair D Henderson, et al.
JACC. Heart Failure
|
March 15, 2025
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
Kieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
JAMA Cardiology
|
April 17, 2024
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial
Ravi B Patel, Frank E Silvestry, Jan Komtebedde, et al.
Diabetes, Obesity & Metabolism
|
April 8, 2024
Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial
Mats C Højbjerg Lassen, Niklas Dyrby Johansen, Daniel Modin, et al.
Page
of 188